HCRN investigators report switch maintenance pembrolizumab leads to additional objective responses, prolongs progression-free survival in some patients with metastatic urothelial cancer

Press/Media

Period27 Jun 2020

Media coverage

1

Media coverage

  • TitleHCRN investigators report switch maintenance pembrolizumab leads to additional objective responses, prolongs progression-free survival in some patients with metastatic urothelial cancer
    Media name/outletIndia Pharma News
    Country/TerritoryIndia
    Date27/06/20
    PersonsMatthew Galsky